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A bstract
The objective of the study was to investigate whe-
ther the lysosom al enzym e, N -A cetyl-β-D-g lucosa-
m in idase (N A G ) activ ity  is  increased in  p lasm a of 
patients w ith acute m yocardial infarction (AMI) and  
to  determ ine if there is  any association betw een  
plasm a levels of N A G  and severity  of m yocardial 
infarction (M I). N A G  activity  in  p lasm a w as m oni-
tored in 69 patients with AMI and 135 norm al heal-
thy subjects using a spectrofluorim etric m ethod. 
A  m odified A ldrich ST elevation  score w as used  
to gauge the severity of M I in term s of size of the  
infarct. Plasma NAG levels in AMI patients and nor-
m al healthy subjects w ere found to  be 10.92±7.5  
U /l and 6.8±2.2 U /l, respectively. These tw o m ean  
value when com pared by Student's t-test were sig -
nificantly different P = 0.0001. No statistically signi-
ficant d ifferences in  N A G  activity  w ere observed  
in  patients in term s of gender, age, location of 
infarct, tim e from  onset of chest pain  to  b lood  
sam pling  in  the hospital and size of the in farct.
Keyw ords: acetylglucosaminidase; biological markers; 
inflammation; lysosomes; myocardial infarction
In troduction
N-Acetyl-β-D-glucosaminidase (NAG) is a lysosomal 
enzyme, which is normarlly present in human plasma 
(Price and Dance, 1972). However, its levels have 
been found to be increased in a number of diseases, 
such as diabetes mellitus (Whiting et al., 1979; 
Severini et al., 1988), liver disease (Severini et al., 
1990) and cancer (Reglero et al., 1980; Severini and 
Aliberti, 1994; Iqbal et al., 1999). NAG activity has 
also been reported to be elevated in inflammatory 
conditions like arthopathies (Iqbal et al., 1999) and 
chronic obstructive pulmonary diseases (Javed et al., 
1996). Since coronary artery disease and myocardial 
infarction (MI) are now also seen as an inflammatory 
conditions and markers like c-reactive protein are 
considered to be strong predictors of risk for future 
cardiovascular events (Libby, 2002), it is imperative 
that the role of other markers of inflammation, such 
as NAG should be studied in acute myocardial in-
farction (AMI).
  The present study was undertaken to investigate 
whether or not NAG activity is increased in AMI 
patients compared to normal healthy subjects and to 
see if there is any association between plasma levels 
of NAG and size of the infarct.
M ateria ls and M ethods
Sixty nine consecutive Pakistani patients with AMI 
were included in this study. All these patients were 
admitted to the coronary care unit of the Aga Khan 
University Hospital between June 1998 to October 
1999. The study had been approved by the Ethical 
Committee of the Aga Khan University. Demographic 
and clinical characteristics of the patients have been 
given in Table 1. Diagnosis of AMI was on the basis 
of clinical history, electrocardiogram (ECG) and bio-
chemical data.
B lood co llection
Ten ml blood was collected from the patients im-
mediately after admission and transferred to a tube 
containing EDTA as anticoagulant. Plasma was im-
mediately removed from it by centrifugation at 1,500 
g for 15 min and stored frozen at -60oC until the time 
of analysis of NAG.
A nalysis of N A G
NAG activity was determined in the plasma samples 
by the method of Whiting et al. (1979) as described 
in a previous publication (Iqbal et al., 1998). Briefly, 
0.1 ml of plasma was diluted with 0.4 ml of distilled 
water. To this was added 4.5 ml of 20 mM citrate- 
phosphate buffer, pH 4.4, containing 0.2 mM methyl-
umbelliferyl-glucosaminidine at 37oC. One ml from this 
was then withdrawn at various time intervals (0 min, 
N -Acetyl-β-D-glucosaminidase in acute myocardial infarction
276   Exp. Mol. Med. Vol. 35(4), 275- 278, 2003
5 min, 10 min, 15 min) and transferred to separate 
tubes containing 2 ml of 0.5 M glycine-NaOH buffer, 
pH 10.4, to stop the reaction.
  The fluorescence of 4-methylumbelliferone (MU) 
released in each reaction was monitored spectrofluor-
imetrically at excitation and emission wavelengths of 
368 and 448 nm, respectively, using JASCO FP-770 
spectrofluorimeter. One unit of NAG activity was defin-
ed as that which released 1 µmole of 4-methylumbelli-
ferone per minute under assay conditions.
Statistical analysis
Mean values have been presented as means±SD. 
Comparison of the two mean values was carried out 
by using Student's t-test. One way ANOVA followed 
by Tukey's HSD test was used for comparison of the 
mean values of more than two groups. P value of＜
0.05 was considered significant.
Severity of M I
Severity of MI in terms of size of the infarct was car-
ried out by using criteria for modified Aldrich ST eleva-
tion score (Porela et al., 1999) as outlined below:
Anterior
  3 × [1.5 × (number of leads with ST elevation
  ≥ 0.1 mV)-0.4]
Inferior
  3 × [0.6 × (∑ST elevation in mV) + 2.0]
  Leads 1, aVL, V5, and V6 were included in the 
anterior and inferior scores according to the primary 
site of epicardial injury: Anterior V1 through V4; In-
ferior II, aVF and III.
  A score of ≤15 was arbitrarily assigned to the 
small infarct; a score between 15.1-25 was assigned 
to the medium size infarct, a score ＞25 was ascrib-
ed to large infarct.
C ontrols
One hundred and thirty five normal healthy subjects 
with the mean age of 48±11.4 years were included 
as controls. They had no evidence of coronary artery 
disease, diabetes mellitus, hypertension, obesity, hyper-
cholesterolemia, liver disease, uremia and malignan-
cy. Those using any medication during the last 24 h 
were also excluded.
R esu lts
Table 1 shows the demographic and clinical charac-
teristics of patients. Male to female ratio was 4:1, and 
6 of them had prior history of MI.
  Figure 1 shows the means±SD plasma NAG acti-
vity in AMI patients and normal healthy subjects. Mean 
plasma levels of NAG in AMI patients and in normal 
healthy subjects were found to be 10.92±7.5 U/l and 
6.8±2.17 Ul, respectively. The mean NAG values in 
these two groups when analyzed by student's t-test 
were found to be significantly different (P = 0.0001).
  Table 2 shows mean value of NAG in AMI patients 
relative to their sex, age, location of infarct and time 
from onset of symptoms to blood sampling for NAG. 
Comparison of the mean NAG values reveals no sta-
tistically significant difference between male and fe-
male groups, older and younger patients groups, and 
groups of patients in whom the time between onset 
of chest pain and blood sampling was ≤90 min, or 
91-180 min, or ＞180 min (as commonly practiced).
Figure  1 . Plasma NAG activity in a group of AMI patients and normal
control group. Comparison of the distribution of NAG values in two 
groups was carried out using Student's t-test.
Tab le  1 . Demographic and clinical characteristics of patients with AMI.
ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ
Variable Value Frequency (%)
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Age 56.8±12.3 years
(range 40-79 years)
Gender 55 males 80
14 females 20
Prior history of MI 6 9
Interval between onset 3.06±2 ha
  of chest pain and
  blood sampling
MI location:
  -Anterior 33 48
  -Inferior 36 52
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
aMeans±SD.
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  Table 3 shows the relationship between the NAG 
activity in plasma of AMI patients and the size of 
infarct on the basis of modified ST elevation Aldrich 
score. Comparison of the mean NAG values in the 
3 groups reveals no statistically significant difference 
suggesting that there was no apparent relationship 
between the plasma levels of NAG and the size of 
infarct in AMI patients.
D iscussion
Plasma level of an enzyme reflects a balance be-
tween rate of its release in extracellular compartment 
and clearance or uptake from the extracellular space 
(Goldberg, 1986). The observed increase of NAG acti-
vity in plasma of AMI patients appears to be due to 
its release from cardiac lysosomes. This is supported 
by the observation that drugs known to stabilize the 
lysosomes during experimental myocardial anoxia cause 
reduction in plasma NAG levels (Welman et al., 1980).
  Our results are in agreement with those reported 
by Welman et al. (1980) and Inoue et al. (2000) who 
have also shown increased levels of NAG in AMI 
patients and in patients with coronary artery disease. 
Though, plasma NAG can arise from other tissues as 
well, due to complications of MI, yet the elevated 
activity observed in AMI patients is less likely to be 
due to that because we monitored NAG activity within 
just few hours after MI. The mean time from onset 
of chest pain to blood sampling in our patients was 
nearly 3 h.
  In our patient populations, we did not find any 
significant difference in NAG values in terms of gen-
der, age, location of infarct, time from onset of chest 
pain to blood sampling in the hospital and size of the 
infarct. Although Inoue et al. (2000) have reported a 
relationship between the activity of NAG and severity 
of coronary artery disease in terms of multi-vessel 
disease and single-vessel disease, yet our data did 
not show any relationship between NAG activity and 
size of the infarct. It may be because of the reason 
that our classification regarding severity of MI was 
based on modified Aldrich ST elevation score, which 
may not be as precise as would be the angiographic 
assessment (Inoue et al., 2000). Moreover, another 
factor for the observed lack of association between 
NAG activity and severity of MI could be the relatively 
small number of patients in our study.
  Our data, however, clearly show that plasma NAG 
activity is elevated in AMI patients. For evaluation of 
its role as a nonspecific diagnostic maker for MI, a 
prospective study comprising a large number of pa-
tients would be required.
A cknow ledgem ent
The study was supported by a grant No. S-AKU-Med 
(185) to Dr. M. Perwaiz Iqbal by the Pakistan Science 
Foundation.
Tab le  2 . Plasma NAG activity in AMI patients relative to gender, age,
position of infarct and time between onset of pain to blood sampling.
ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ
Variable Number (n) NAG(U/l) P-valuea
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Gender:
  - Male 55 11.11 ± 8.21 0.68
  - Female 14 10.17 ± 3.94
Age:
  - ≤ 57 years 37 12.46 ± 9.47 0.067
  - ＞ 57 years 32  9.13 ± 3.72
Location of Infarct:
  - Anterior 33 10.77 ± 7.92 0.88
  - Inferior 36 11.04 ± 7.25
Time (onset of pain to sampling):
  0-90 min 19 12.1 ± 8.6 0.388
  90-180 min 26 11.6 ± 9.3
  ＞180 min 24  9.2 ± 3.3
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
aP-value compares the groups within that variable.
T a b le  3 . Comparison of the distribution of NAG values in 3 groups of AMI patients (representing small, medium and large size infarcts) on
the basis of modified Aldrich ST elevation score.
ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ
Modified Classification basedGroup No. (n) NAG (U/l) P-valueaaldrich score on size of infarct
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
1 ≤15 Small 16 11.9 ± 7.3 NS
2 15.1-25 Medium 40 10.3 ± 7.3 NS
3 ＞25 Large 13 11.7 ± 8.8 NS
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
aP-value compares the mean values in the 3 groups using one way ANOVA.
NS, Not significant.
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